Skip to main content
SpringerLink
Log in

Reirradiation with radiosurgery or stereotactic fractionated radiotherapy in association with regorafenib in recurrent glioblastoma

  • Original Article
  • Published:
Strahlentherapie und Onkologie Aims and scope Submit manuscript

Abstract

Purpose

No standard treatment has yet been established for recurrent glioblastoma (GBM). In this context, the aim of the current study was to evaluate safety and efficacy of reirradiation (re-RT) by radiosurgery or fractionated stereotactic radiotherapy (SRS/FSRT) in association with regorafenib.

Methods

Patients with a histological or radiological diagnosis of recurrent GBM who received re-RT by SRS/FSRT and regorafenib as second-line systemic therapy were included in the analysis.

Results

From January 2020 to December 2022, 21 patients were evaluated. The median time between primary/adjuvant RT and disease recurrence was 8 months (range 5–20). Median re-RT dose was 24 Gy (range 18–36 Gy) for a median number of 5 fractions (range 1–6). Median regorafenib treatment duration was 12 weeks (range 3–26). Re-RT was administered before starting regorafenib or in the week off regorafenib during the course of chemotherapy. The median and the 6‑month overall survival (OS) from recurrence were 8.4 months (95% confidence interval [CI] 6.9–12.7 months) and 75% (95% CI 50.9–89.1%), respectively. The median progression-free survival (PFS) from recurrence was 6 months (95% CI 3.7–8.5 months). The most frequent side effects were asthenia that occurred in 10 patients (8 cases of grade 2 and 2 cases of grade 3), and hand–foot skin reaction (2 patients grade 3, 3 patients grade 2). Adverse events led to permanent regorafenib discontinuation in 2 cases, while in 5/21 cases (23.8%), a dose reduction was administered. One patient experienced dehiscence of the surgical wound after reintervention and during regorafenib treatment, while another patient reported intestinal perforation that required hospitalization.

Conclusion

For recurrent GBM, re-RT with SRT/FSRT plus regorafenib is a safe treatment. Prospective trials are necessary.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistics, 2006. CA Cancer J Clin 56(2):106–130. https://doi.org/10.3322/canjclin.56.2.106

    Article  PubMed  Google Scholar 

  2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bog-dahn U et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. https://doi.org/10.1056/NEJMoa043330

    Article  CAS  PubMed  Google Scholar 

  3. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5‑year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466. https://doi.org/10.1016/S1470-2045(09)70025-7

    Article  CAS  PubMed  Google Scholar 

  4. Biswas T, Okunieff P, Schell MC, Smudzin T, Pilcher WH, Bakos RS, Vates GE, Walter KA, Wensel A, Korones DN et al (2009) Stereotactic radiosurgery for glioblastoma: retrospective analysis. Radiat Oncol 4:11. https://doi.org/10.1186/1748-717X-4-11

    Article  PubMed  PubMed Central  Google Scholar 

  5. Niranjan A, Kano H, Iyer A, Kondziolka D, Flickinger JC, Lunsford LD (2015) Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era. J Neurosurg 122:757–765. https://doi.org/10.3171/2014.11.JNS13295

    Article  PubMed  Google Scholar 

  6. Park KJ, Kano H, Iyer A, Liu X, Niranjan A, Flickinger JC, Lieberman FS, Lunsford LD, Kondziolka D (2012) Salvage gamma knife stereotactic radiosurgery followed by bevacizumab for recurrent glioblastoma multiforme: a case-control study. J Neurooncol 107:323–333. https://doi.org/10.1007/s11060-011-0744-9

    Article  CAS  PubMed  Google Scholar 

  7. Patel M, Siddiqui F, Jin JY, Mikkelsen T, Rosenblum M, Movsas B, Ryu S (2009) Salvage reirradiation for recurrent glioblastoma with radiosurgery: Radiographic response and improved survival. J Neurooncol 92:185–191. https://doi.org/10.1007/s11060-008-9752-9

    Article  PubMed  Google Scholar 

  8. Skeie BS, Enger PØ, Brøgger J, Ganz JC, Thorsen F, Heggdal JI, Pedersen PH (2012) γ knife surgery versus reoperation for recurrent glioblastoma multiforme. World Neurosurg 78:658–669. https://doi.org/10.1016/j.wneu.2012.03.024

    Article  PubMed  Google Scholar 

  9. Bräutigam E, Lampl C, Track C, Nieder C, Pichler J, Hammer J, Geinitz H (2019) Re-irradiation of recurrent glioblastoma as part of a sequential multimodality treatment concept. Clin Transl Oncol 21:582–587. https://doi.org/10.1007/s12094-018-1957-6

    Article  PubMed  Google Scholar 

  10. Frischer JM, Marosi C, Woehrer A, Hainfellner JA, Dieckmann KU, Eiter H, Wang WT, Mallouhi A, Ertl A, Knosp E et al (2016) Gamma knife radiosurgery in recurrent glioblastoma. Stereotact Funct Neurosurg 94:265–272. https://doi.org/10.1159/000448924

    Article  PubMed  Google Scholar 

  11. Yazici G, Cengiz M, Ozyigit G, Eren G, Yildiz F, Akyol F, Gurkaynak M, Zorlu F (2014) Hypofractionated stereotactic reirradiation for recurrent glioblastoma. J Neurooncol 120:117–123. https://doi.org/10.1007/s11060-014-1524-0

    Article  PubMed  Google Scholar 

  12. Martínez-Carrillo M, Tovar-Martín I, Zurita-Herrera M, Del Moral-Ávila R, Guerrero-Tejada R, Saura-Rojas E, Osorio-Ceballos JL, Arrebola-Moreno JP, Expósito-Hernández J (2014) Salvage radiosurgery for selected patients with recurrent malignant gliomas. Biomed Res Int 2:657953

    Google Scholar 

  13. National Comprehensive Cancer Network (2022) Central Nervous System Cancers. https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed 1 Feb 2023

  14. Bloch O, Han SJ, Cha S, Sun MZ, Aghi MK, McDermott MW, Berger MS, Parsa AT (2012) Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article. J Neurosurg 117:1032–1038. https://doi.org/10.3171/2012.9.JNS12504

    Article  PubMed  Google Scholar 

  15. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733–4740. https://doi.org/10.1200/JCO.2008.19.8721

    Article  CAS  PubMed  Google Scholar 

  16. Lombardi G, De Salvo GL, Brandes AA, Eoli M, Rudà R, Faedi M, Lolli I, Pace A, Daniele B, Pasqualetti F et al (2019) Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): A multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol 20:110–119. https://doi.org/10.1016/S1470-2045(18)30675-2

    Article  CAS  PubMed  Google Scholar 

  17. Navarria P, Minniti G, Clerici E, Tomatis S, Pinzi V, Ciammella P, Galaverni M, Amelio D, Scartoni D, Scoccianti S et al (2019) Re-irradiation for recurrent glioma: Outcome evaluation, toxicity and prognostic factors assessment. A multicenter study of the Radiation Oncology Italian Association (AIRO). J Neurooncol 142:59–67. https://doi.org/10.1007/s11060-018-03059-x

    Article  CAS  PubMed  Google Scholar 

  18. Mazzola R, Corradini S, Gregucci F, Figlia V, Fiorentino A, Alongi F (2019) Role of radiosurgery/stereotactic radiotherapy in oligometastatic disease: brain oligometastases. Front Oncol 9:206. https://doi.org/10.3389/fonc.2019.00206

    Article  PubMed  PubMed Central  Google Scholar 

  19. Meduri B, Gregucci F, D’Angelo E, Alitto AR, Ciurlia E, Desideri I, Marino L, Borghetti P, Fiore M, Fiorentino A, AIRO Giovani -Italian Association of Radiation Oncology-Young Members (2020) Volume de-escalation in radiation therapy: state of the art and new perspectives. J Cancer Res Clin Oncol 146:909–924. https://doi.org/10.1007/s00432-020-03152-7

    Article  PubMed  Google Scholar 

  20. Gregucci F, Surgo A, Carbonara R, Laera L, Ciliberti MP, Gentile MA et al (2022) Radiosurgery and stereotactic brain radiotherapy with systemic therapy in recurrent high-grade gliomas: is it feasible? Therapeutic strategies in recurrent high-grade Gliomas. J Pers Med 12(8):1336. https://doi.org/10.3390/jpm12081336

    Article  PubMed  PubMed Central  Google Scholar 

  21. Fogh SE, Andrews DW, Glass J, Curran W, Glass C, Champ C, Evans JJ, Hyslop T, Pequignot E, Downes B et al (2010) Hypofractionated stereotactic radiation therapy: An effective therapy for recurrent high-grade gliomas. J Clin Oncol 28:3048–3053. https://doi.org/10.1200/JCO.2009.25.6941

    Article  PubMed  PubMed Central  Google Scholar 

  22. Holt DE, Bernard ME, Quan K, Clump DA, Engh JA, Burton SA, Heron DE (2016) Salvage stereotactic radiosurgery for recurrent glioblastoma multiforme with prior radiation therapy. J Cancer Res Ther 12:1243–1248. https://doi.org/10.4103/0973-1482.199537

    Article  CAS  PubMed  Google Scholar 

  23. Martínez-Garcia M, Álvarez-Linera J, Carrato C, Ley L, Luque R, Maldonado X, Martínez-Aguillo M, Navarro LM, Vaz-Salgado MA, Gil-Gil M (2018) SEOM clinical guidelines for diagnosis and treatment of glioblastoma. Clin Transl Oncol 20:22–28. https://doi.org/10.1007/s12094-017-1763-6

    Article  PubMed  Google Scholar 

  24. Torok JA, Wegner RE, Mintz AH, Heron DE, Burton SA (2011) Re-irradiation with radiosurgery for recurrent glioblastoma multiforme. Technol Cancer Res Treat 10:253–258. https://doi.org/10.7785/tcrt.2012.500200

    Article  CAS  PubMed  Google Scholar 

  25. Gigliotti MJ, Hasan S, Karlovits SM, Ranjan T, Wegner RE Re-irradiation with stereotactic radiosurgery/radiotherapy for recurrent high-grade gliomas: Improved survival in the modern era. Stereotact Funct Neurosurg 96:289–295. https://doi.org/10.1159/000493545

  26. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216. https://doi.org/10.1093/jnci/92.3.205

    Article  CAS  PubMed  Google Scholar 

  27. Alongi F, Fiorentino A, Gregucci F, Corradini S, Giaj-Levra N, Romano L, Rigo M, Ricchetti F, Beltramello A, Lunardi G et al (2019) First experience and clinical results using a new non-coplanar mono-isocenter technique (HyperArc™) for Linac-based VMAT radiosurgery in brain metastases. J Cancer Res Clin Oncol 145:193–200. https://doi.org/10.1007/s00432-018-2781-7

    Article  CAS  PubMed  Google Scholar 

  28. Gregucci F, Bonaparte I, Surgo A, Caliandro M, Carbonara R, Ciliberti MP, Aga A, Berloco F, De Masi M, De Pascali C et al (2021) Brain linac-based radiation therapy: “test drive” of new immobilization solution and surface guided radiation therapy. J Pers Med 11:1351. https://doi.org/10.3390/jpm11121351

    Article  PubMed  PubMed Central  Google Scholar 

  29. Gregucci F, Surgo A, Bonaparte I, Laera L, Ciliberti MP, Carbonara R, Gentile MA, Giraldi D, Calbi R, Caliandro M et al (2021) Poor-prognosis patients affected by glioblastoma: retrospective study of hypofractionated radiotherapy with simultaneous integrated boost and concurrent/Adjuvant Temozolomide. J Pers Med 11:1145. https://doi.org/10.3390/jpm11111145

    Article  PubMed  PubMed Central  Google Scholar 

  30. Stiefel I, Schröder C, Tanadini-Lang S, Pytko I, Vu E, Klement RJ, Guckenberger M, Andratschke N et al (2021) High-dose re-irradiation of intracranial lesions—Efficacy and safety including dosimetric analysis based on accumulated EQD2Gy dose EQD calculation. Clin Transl Radiat Oncol 27:132–138. https://doi.org/10.1016/j.ctro.2021.01.011

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, Bendszus M, Balana C, Chinot O, Dirven L et al (2021) EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 18(3):170–186. https://doi.org/10.1038/s41571-020-00447-z

    Article  PubMed  Google Scholar 

  32. Hau P, Baumgart U, Pfeifer K, Bock A, Jauch T, Dietrich J, Fabel K, Grauer O, Wismeth C, Klinkhammer-Schalke M et al (2003) Salvage therapy in patients with glioblastoma: Is there any benefit? Cancer 98:2678–2686. https://doi.org/10.1002/cncr.11845

    Article  PubMed  Google Scholar 

  33. Kondziolka D, Flickinger JC, Bissonette DJ, Bozik M, Lunsford LD (1997) Survival benefit of stereotactic radiosurgery for patients with malignant glial neoplasms. Neurosurgery 41:776–783. https://doi.org/10.1097/00006123-199710000-00004 (discussion 783–5)

    Article  CAS  PubMed  Google Scholar 

  34. Gutin PH, Iwamoto FM, Beal K, Mohile NA, Karimi S, Hou BL, Lymberis S, Yamada Y, Chang J, Abrey LE (2009) Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 75:156–163. https://doi.org/10.1016/j.ijrobp.2008.10.043

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Vordermark D, Kölbl O, Ruprecht K, Vince GH, Bratengeier K, Flentje M (2005) Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma. BMC Cancer 5:55. https://doi.org/10.1186/1471-2407-5-55

    Article  PubMed  PubMed Central  Google Scholar 

  36. Yaprak G, Isık N, Gemici C, Pekyurek M, Ceylaner Bıcakcı B, Demircioglu F, Tatarlı N (2020) Stereotactic radiotherapy in recurrent Glioblastoma: a valid salvage treatment option. Stereotact Funct Neurosurg 98:167–175. https://doi.org/10.1159/000505706

    Article  PubMed  Google Scholar 

  37. Conti A, Pontoriero A, Arpa D, Siragusa C, Tomasello C, Romanelli P, Cardali S, Granata F, De Renzis C, Tomasello F (2012) Efficacy and toxicity of CyberKnife re-irradiation and “dose dense” temozolomide for recurrent gliomas. Acta Neurochir 154:203–209. https://doi.org/10.1186/s40064-015-0804-2

    Article  PubMed  Google Scholar 

  38. Flieger M, Ganswindt U, Schwarz SB, Kreth FW, Tonn JC, la Fougère C, Ertl L, Linn J, Herrlinger U, Belka C et al (2014) Re-irradiation and bevacizumab in recurrent high grade glioma: An effective treatment option. J Neurooncol 117:337–345. https://doi.org/10.1007/s11060-014-1394-5

    Article  CAS  PubMed  Google Scholar 

  39. Tsien CI, Pugh SL, Dicker AP, Raizer JJ, Matuszak MM, Lallana EC, Huang J, Algan O, Deb N, Portelance L, Villano JL, Hamm JT, Oh KS, Ali AN, Kim MM, Lindhorst SM, Mehta MP (2023) NRG oncology/RTOG1205: a randomized phase II trial of concurrent bevacizumab and reirradiation versus bevacizumab alone as treatment for recurrent Glioblastoma. J Clin Oncol 41(6):1285–1295. https://doi.org/10.1200/JCO.22.00164

    Article  CAS  PubMed  Google Scholar 

  40. Navarria P, Pessina F, Clerici E, Bellu L, Franzese C, Franzini A, Simonelli M, Bello L, Santoro A, Politi LS et al (2022) Re-irradiation for recurrent high-grade glioma (HGG) patients: results of a single arm prospective phase 2 study. Radiother Oncol 167:89–96. https://doi.org/10.1016/j.radonc.2021.12.019

    Article  CAS  PubMed  Google Scholar 

  41. Balducci M, Chiesa S, Diletto B, D’Agostino GR, Mangiola A, Manfrida S, Mantini G, Albanese A, Fiorentino A, Frascino V, De Bari B, Micciche’ F, De Rose F, Morganti AG, Anile C, Valentini V (2012) Low-dose fractionated radiotherapy and concomitant chemotherapy in glioblastoma multiforme with poor prognosis: a feasibility study. Neuro Oncol 14(1):79–86. https://doi.org/10.1093/neuonc/nor173

    Article  CAS  PubMed  Google Scholar 

  42. Song CW, Cho LC, Yuan J et al (2013) Radiobiology of stereotactic body radiation therapy/stereotactic radiosurgery and the linear-quadratic model. Int J Radiat Oncol Biol Phys 87(1):18–19. https://doi.org/10.1016/j.ijrobp.2013.03.013

    Article  PubMed  Google Scholar 

  43. Wilhelm SM, Dumas J, Adnane L et al (2011) Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129:245–255. https://doi.org/10.1002/ijc.25864

    Article  CAS  PubMed  Google Scholar 

  44. Daudigeos-Dubus E, Le Dret L, Lanvers-Kaminsky C et al (2015) Regorafenib: antitumor activity upon mono and combination therapy in preclinical pediatric malignancy models. PLoS ONE 10:e142612. https://doi.org/10.1371/journal.pone.0142612

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Miulli General Regional Hospital, Acquaviva delle Fonti-Bari, Italy

    Fabiana Gregucci M.D., Fiorella Cristina Di Guglielmo, Alessia Surgo, Roberta Carbonara, Maria Paola Ciliberti, Morena Caliandro, Valerio Davi’, Ilaria Bonaparte & Alba Fiorentino

  2. Department of Medical Oncology, Miulli General Regional Hospital, Acquaviva delle Fonti-Bari, Italy

    Letizia Laera, Nicola Sasso & Giammarco Surico

  3. Department of Radiology, Miulli General Regional Hospital, Acquaviva delle Fonti-Bari, Italy

    Maria Annunziata Gentile & Roberto Calbi

  4. Department of Neurosurgery, Miulli General Regional Hospital, Acquaviva delle Fonti-Bari, Italy

    Vincenzo Fanelli & David Giraldi

  5. Centro Orientamento Oncologico (COrO), Miulli General Regional Hospital, Acquaviva delle Fonti-Bari, Italy

    Romina Tortora

  6. Department of Medical Oncology, Ospedale San Paolo, Bari, Italy

    Valeria Internò & Francesco Giuliani

  7. Division of Neurosurgery, Department of Translational Biomedicine and Neurosciences (DiBraiN), University “Aldo Moro” of Bari, Bari, Italy

    Francesco Signorelli

  8. Department of Medical Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy

    Giuseppe Lombardi

  9. Department of Medicine and Surgery, LUM University, Casamassima-Bari, Italy

    Alba Fiorentino

Authors
  1. Fabiana Gregucci M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fiorella Cristina Di Guglielmo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alessia Surgo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Roberta Carbonara
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Letizia Laera
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maria Paola Ciliberti
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Maria Annunziata Gentile
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Roberto Calbi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Morena Caliandro
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Nicola Sasso
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Valerio Davi’
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Ilaria Bonaparte
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Vincenzo Fanelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. David Giraldi
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Romina Tortora
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Valeria Internò
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Francesco Giuliani
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Giammarco Surico
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Francesco Signorelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Giuseppe Lombardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Alba Fiorentino
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fabiana Gregucci M.D..

Ethics declarations

Conflict of interest

F. Gregucci, F.C. Di Guglielmo, A. Surgo, R. Carbonara, L. Laera, M.P. Ciliberti, M.A. Gentile, R. Calbi, M. Caliandro, N. Sasso, V. Davi’, I. Bonaparte, V. Fanelli, D. Giraldi, R. Tortora, V. Internò, F. Giuliani, G. Surico, F. Signorelli, G. Lombardi, and A. Fiorentino declare that they have no competing interests.

Ethical standards

This article does not contain any studies with human participants performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The authors F. Gregucci and F.C. Di Guglielmo share first authorship.

The authors G. Lombardi and A. Fiorentino share last authorship.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gregucci, F., Di Guglielmo, F.C., Surgo, A. et al. Reirradiation with radiosurgery or stereotactic fractionated radiotherapy in association with regorafenib in recurrent glioblastoma. Strahlenther Onkol (2023). https://doi.org/10.1007/s00066-023-02172-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00066-023-02172-9

Keywords

Search

Navigation